Saltikva
Stage 4, metastatic pancreatic cancer
Phase 2Active
Key Facts
About Salspera
Salspera is a private, pre-revenue biotech founded in 2021, advancing its lead candidate Saltikva for Stage 4 pancreatic cancer. Phase 2 data demonstrated promising signals of reduced tumor burden and improved survival when added to standard chemotherapy, with a favorable safety profile. The company is positioned to address a high-unmet-need oncology market with a potentially differentiated combination therapy. Its near-term focus will be on advancing Saltikva through further clinical development.
View full company profile